Venture Capital

Latest Headlines

Latest Headlines

Proteon banks $45M for vascular drug with Novartis in the rearview

With $45 million in venture commitments under its belt, Proteon is set to roll into a late-stage study for its top candidate, with no need for Big Pharma help.

ZS Pharma looks to $86M IPO to fund PhIII hyperkalemia studies

ZS Pharma is executing a familiar biotech gambit. The Texas-based biotech raised $55 million from some top venture groups just a few weeks ago, and now it's formally moving ahead with an $86 million IPO.

Chase banks $21M round for Alzheimer's drug research

Promising to use its technology to enhance the efficacy and safety of currently approved Alzheimer's drugs, Chase Pharmaceuticals says it has now added $21 million in new venture cash.

Flatiron raises $130M in Google-led round, buys EMR business

Google Ventures' reported $100 million investment in oncology Big Data startup Flatiron Health came to fruition this week. And the deal is even bigger than early reports suggested, with Flatiron raising $130 million and buying electronic medical record business Altos Solutions.

Novartis-backed ImaginAb banks $21M for antibody tech

UCLA brainchild ImaginAb has hauled in another $21 million in venture cash to advance its antibody-re-engineering technology, a biotech approach to imaging that the company believes will help personalize treatments for cancer and immune disease.

Marquee VCs back a $37.5M launch round for immune-tolerant drugs

A spinoff from the Ecole Polytechnique Fédérale de Lausanne has rounded up a hefty $37.5 million A round from a prominent group of biotech investors to develop a new-and-improved portfolio of immune-tolerant therapies.

Loxo lands $24M venture round and a CSO for cancer drug research

After recruiting a chief scientific officer from Epizyme, upstart cancer drug developer Loxo Oncology has nabbed a $24 million B round from some marquee venture players. New Enterprise Associates came in to lead this round, buying into the business plan of focusing on genetically-defined cancers, with existing investors Aisling Capital and OrbiMed Advisors joining in.

Naurex picks up $25M to get its depression drugs through PhII

Evanston, IL's Naurex nailed down another $25 million in venture funding to accelerate its two-pronged depression program, posting positive midstage results for its top prospect.

Enterome raises $11.5M for gut microbiome R&D

Paris-based Enterome Bioscience, focused on the gut microbiome, has raised €10 million ($11.5 million) in the first tranche of its Series B fundraising. Seventure (including from its new Health for Life Capital fund), Lundbeckfond Ventures and Omnes Capital contributed cash to the deal.

VC Lightstone lands $172M fund with an eye on biotech startups

Lightstone Ventures, the life sciences-focused progeny of two VC stalwarts, has wrapped up a fund of its own, setting out with $172 million to back early-stage drug and med tech companies.